CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers ...
CARLSBAD, Calif., Jan. 26, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral ...
CARLSBAD, Calif., July 30, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today it has begun commercial shipments of its FastPack ® SARS-CoV-2 IgG ...
CARLSBAD, Calif., Nov. 28, 2018 /PRNewswire/ -- Qualigen, Inc., a privately-owned company that provides novel diagnostic and therapeutic technologies for the treatment of cancer and infectious ...
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics The all cash transaction, which closed ...
Qualigen Therapeutics Inc, a biotechnology company, announced agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of diagnostic test ...
In June 2022, Qualigen Therapeutics, Inc. QLGN announced it has commenced Investigational New Drug (IND)-enabling studies for its lead therapeutic program, QN-302, which include initial safety and ...
CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ...
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results